12057 Surgical Stress-Buster: Dexamethasone's Role in Robotic Hysterectomy

Minimally invasive surgery has revolutionized the field of surgical interventions with its numerous advantages such as reduced postoperative pain, faster recovery, and shorter hospital stays. The anti-inflammatory effects of dexamethasone is well documented; evoking interest in studies on the potential benefit in surgical procedures. Numerous studies have investigated the use of dexamethasone in the context of laparoscopic surgery but less so in the gynecologic robotic field. We evaluated of the effect of 24 mg dexamethasone on surgical stress, pain and recovery in robotic hysterectomy. We performed the first ever double-blinded randomized study on dexamethasone in benign robotic hysterectomy (NCT04762381). Blood sampling and visual analog scale (VAS) for pain and medications and sexuality and incontinence were obtained. Women scheduled for benign robotic hysterectomy in hospital setting. Women with benign indication for hysterectomy excluding co-morbidities diabetes, malignant disease or chronic pain. In 2022-24 women were randomized to a single dose of either saline (n=58) or 24 mg dexamethasone (n=51) 15 minutes before surgery. 109 women had complete blood sampling at all-time points. Their average age was 48 years (range 23-75), parity 1.6 (0-2), BMI 29 kg/m2 (18-44), and 17 were current users of estrogen. The VAS was 0.5 (0-5) at baseline and 2.3 (0-10) 24 h after operation, similar in both groups. The c-reactive protein was significantly lower in the dexamethasone group at 12h 7.5 mg/L (95% CI; 5.7-9.2) vs. 11.5 (95% CI;9-14) in controls. Similarly, at 24h 19.7 (13-27) vs. 48.8 (39-59) in the dexamethasone group vs. controls. At present, no difference between the groups is found in the questionnaires on recovery and symptoms. The effect of dexamethasone on c-reactive protein indicating a reduction of the perceived surgical stress response. Further results and in particular, those of the underlying response modulators will be presented.

Authors

Institutions

Publication Details

Journal
Journal of Minimally Invasive Gynecology
Published
2024-11-01
DOI
https://doi.org/10.1016/j.jmig.2024.09.886
Primary Topic
Cardiac, Anesthesia and Surgical Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

12057 Surgical Stress-Buster: Dexamethasone's Role in Robotic Hysterectomy

Finn Friis Lauszus, KA Nielsen, Thomas Strøm, Kurt Kaiser et al.
Journal of Minimally Invasive Gynecology
Cardiac, Anesthesia and Surgical Outcomes
article

12057 Surgical Stress-Buster: Dexamethasone's Role in Robotic Hysterectomy

Finn Friis Lauszus, KA Nielsen, Thomas Strøm, Kurt Kaiser, Alexandros N. Valsamidis, Ismail Gögenür
article en

Abstract

Minimally invasive surgery has revolutionized the field of surgical interventions with its numerous advantages such as reduced postoperative pain, faster recovery, and shorter hospital stays. The anti-inflammatory effects of dexamethasone is well documented; evoking interest in studies on the potential benefit in surgical procedures. Numerous studies have investigated the use of dexamethasone in the context of laparoscopic surgery but less so in the gynecologic robotic field. We evaluated of the effect of 24 mg dexamethasone on surgical stress, pain and recovery in robotic hysterectomy. We performed the first ever double-blinded randomized study on dexamethasone in benign robotic hysterectomy (NCT04762381). Blood sampling and visual analog scale (VAS) for pain and medications and sexuality and incontinence were obtained. Women scheduled for benign robotic hysterectomy in hospital setting. Women with benign indication for hysterectomy excluding co-morbidities diabetes, malignant disease or chronic pain. In 2022-24 women were randomized to a single dose of either saline (n=58) or 24 mg dexamethasone (n=51) 15 minutes before surgery. 109 women had complete blood sampling at all-time points. Their average age was 48 years (range 23-75), parity 1.6 (0-2), BMI 29 kg/m2 (18-44), and 17 were current users of estrogen. The VAS was 0.5 (0-5) at baseline and 2.3 (0-10) 24 h after operation, similar in both groups. The c-reactive protein was significantly lower in the dexamethasone group at 12h 7.5 mg/L (95% CI; 5.7-9.2) vs. 11.5 (95% CI;9-14) in controls. Similarly, at 24h 19.7 (13-27) vs. 48.8 (39-59) in the dexamethasone group vs. controls. At present, no difference between the groups is found in the questionnaires on recovery and symptoms. The effect of dexamethasone on c-reactive protein indicating a reduction of the perceived surgical stress response. Further results and in particular, those of the underlying response modulators will be presented.

Journal of Minimally Invasive GynecologyVol. 31(11)
University of Southern Denmark (DK), Zealand University Hospital (DK), Region of Southern Denmark (DK)
Openalex Percentile: Top 63%
Cardiac, Anesthesia and Surgical Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.